Skip to main content
. Author manuscript; available in PMC: 2014 Jan 3.
Published in final edited form as: Melanoma Res. 2008 Aug;18(4):10.1097/CMR.0b013e3283046146. doi: 10.1097/CMR.0b013e3283046146

Table 4.

Correlation among phosphorylated (p) AKT expression, clinical benefit and changes in receptor protein kinase expression

Correlation of change in pAKT
expression with
Pearson’s correlation coefficient P-value
Clinical response (PR) −0.45 0.23
Clinical benefit (PR + SD) −0.37 0.32
Change in C-KIT expression 0.31 0.42
Change in PDGFR-α expression 0.37 0.33
Change in PDGFR-β expression 0.21 0.59

Changes in protein expression were categorized as follows: −1, decrease; 0, no change; +1, increase. For clinical response, partial response (PR) was coded as 1 and others as 0. For clinical benefit, PR or stable disease (SD) was coded as 1 and others as 0.